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Objective: The present study was designed to investigate the role of protein kinase C (PKC) and phospholipase D (PLD) in
angiotensin II (AngII)- and phorbol ester (PMA)-induced cyclooxygenase-2 (COX-2) expression and prostacyclin (PGI2) production in rat
aortic smooth muscle cells (VSMC). Methods: Prostacyclin production in cultured VSMC was determined by radioimmunoassay. PKC
activity was examined by measuring the transfer of 32P from (g-32P)ATP to histone III-S. COX-2 expression was determined by Western
blotting. To measure PLD activity, thin layer chromatography was used. Results: AngII (50 nM) and PMA (100 nM) promoted the
translocation of PKC activity from the cytosol to the membranes within 30 min, followed by a strong increase in PLD activity as well as
COX-2 expression and PGI2 production. After 48 h exposure to PMA, PKC was downregulated resulting in a complete suppression of its
activity. PKC-downregulation and the PKC inhibitor CGP41251 abolished PMA- and AngII-induced PLD activation, suppressed the
stimulatory effect of PMA on COX-2 expression and PGI2 production and strongly inhibited that of AngII. Furthermore, AngII- and
PMA-induced PGI2 production depended on protein synthesis and COX-2 but not COX-1 activity. Inhibition of PLD-mediated
phosphatidic acid (PA) formation by 1% 1-butanol abolished AngII-induced COX-2 expression and PGI2 secretion, while dioctanoyl PA
increased COX-2 expression and PGI2 production in a time- and concentration-dependent manner. Conclusion: Our results indicate that in
VSMC, AngII promotes PGI2 production to a large extent through a rise in COX-2 expression which is mediated by PA generated from
increased PKC-dependent PLD activity.
D 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Cell culture/isolation; Hormones; Signal transduction; Prostaglandins
1. Introduction expressed in most cell types and appears to be responsibleProstacylin (PGI2), a potent vasodilator and inhibitor of
platelet aggregation, contributes to the maintance of vascu-
lar homeostasis. The formation of PGI2 is regulated at two
rate-limiting steps: release of arachidonic acid (AA) from
membrane phospholipids by phospholipase A2 (PLA2) and
conversion of AA to a prostanoid precursor by the enzyme
cyclooxygenase (COX). Two types of COX, COX-1 and
COX-2 have been identified [1]. COX-1 is constitutively0008-6363/$ - see front matter D 2003 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2003.08.007
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E-mail address: ursula.lang@medecine.unige.ch (U. Lang).for the synthesis of prostaglandins that are important for
homeostatic fonctions, while COX-2 is rapidly induced by
cytokines and growth factors [1].
The vasoactive hormone angiotensin II (AngII) is
known to promote prostaglandins and prostacyclin pro-
duction in various cells including vascular smooth muscle
cells (VSMC). Ohnaka et al. [2] have shown that AngII
induces COX-2 expression and prostaglandin E2 (PGE2)
production, and that COX-2 is regulated by p42/44 and
p38 MAPK in aortic smooth muscle cells. Recently,
AngII has been found to activate cytosolic cPLA2 gen-
erating the metabolite 20-HETE which in turn stimulates
PLD [3] leading to AA release in VSMC. Moreover,
activation of PLD occurs through interaction with theed by Elsevier B.V. All rights reserved.
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Rac/Rho families [6] as well as with protein kinase C
[7]. However, the contribution of these factors to the
activation of PLD depends on the cell type and signaling
model investigated. Both, PKC-dependent and -indepen-
dent activation of PLD has been reported in various
agonist-stimulated cell types [8–11].
Two studies provide evidence that PGI2 synthesis is
limited by the expression levels of COX-2, and that
there is a link between PLD and interleukin-1h- and
PMA-stimulated PGI2 production in amnionic WISH
cells [12,13], but there is no information concerning this
link in VSMC. In this study, we investigated the
possible role of PKC and PLD activation in AngII-
and PMA-induced COX-2 expression and PGI2 secretion
in VSMC.2. Materials and methods
2.1. Materials
[Ile5]Angiotensin II (AngII) was from Bachem (Buben-
dorf, Switzerland). 3H-labeled 6-keto-prostaglandin F1a
(6-keto-PGF1a) and [g-
32P]-ATP were obtained from
Amersham International (Bucks, UK). [3H]-arachidonic
acid and [3H]-oleic acid were from Du Pont de Nemours
International (Regensdorf, Switzerland). Valeryl salicylate
and NS-398 were from Cayman Chemical (Ann Arbor,
MI). Collagenase and elastase were from Sigma (St
Louis, MO).
2.2. Preparation of rat aortic smooth muscle cells
Rat aortic smooth muscle cells (VSMC) were isolated
by enzymatic dispersion of the thoracic aortas of 40–50
days old Wistar rats as previously described [14,15]. The
investigation conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1966). Briefly, the aorta was opened longitudinally on
the dorsal part. The endothelium was gently scraped
using a surgical blade and the media was carefully
dissected from the underlying adventitia. Smooth muscle
cells were isolated from the media by enzymatic diges-
tion. Following dispersion, cells were plated in Petri
dishes or in six-well plates and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal
calf serum. Confluent cultures were passaged, and cells
of the third to the sixth passage were used for all
experiments described in this study. By using antibodies
recognizing alpha-smooth muscle actin (specific of
smooth muscle cells) and factor VIII (specific of endo-
thelial cells), it has been shown that the contamination of
smooth muscle cells by endothelial cells in primary
culture was negligible [14].2.3. Determination of prostacyclin production
VSMC, seeded into six-well plates, were washed and
incubated for 20 min at 37 jC with 1 ml of a Krebs–
Ringer buffer [15], containing 0.2% bovine serum albu-
min and 0.2% glucose. The supernatant was replaced by
fresh buffer, and cells were stimulated at 37 jC. PGI2
production was determined by radioimmunoassay of 50
Al aliquots of the incubation medium for 6-keto-PGF1a,
the stable metabolite of PGI2. Relative affinity of the
anti-6-keto-PGF1a (Oxford Biomedical Research, Oxford
USA) for eicosanoids was given as follows: 100% for 6-
keto-PGF1a, < 1% for PGE2, PGF2a, PGD2, PGE1,
PGF1a and thromboxane B2. Non-specific binding was
estimated at 2.9F 0.11% (n = 10). The detection limit for
6-keto-PGF1a determinations was 3 pg/ml of incubation
medium, while the intra- and interassay coefficients of
variation were evaluated at 4% and 5%, respectively
(n = 10).
2.4. Western blot analysis
After stimulation, VSMC were washed twice with cold
PBS (137 mM NaCl, 1.47 mM KH2PO4, 8.9 mM
Na2HPO4, pH 7.4) and lysed with 500 Al of the following
buffer: Tris/HCl (50 mM, pH 7.4), 1% Triton X-100, 150
mM NaCl, 10% glycerol, 2 mM EDTA, 2 mM EGTA, 40
mM h-glycerophosphate, 50 mM NaF, 10 mM sodium
pyrophosphate, 0.3 mM leupeptin, 1 AM pepstatin A and
1 mM PMSF. Cell lysates (20 Ag) were analysed by SDS-
PAGE at 150 V for 1 h. After transfer, the nitrocellulose
membranes were incubated for 2 h at room temperature
with a polyclonal antibody raised against type II cyclo-
oxygenase (Cayman Chemical).
The membranes were washed and incubated for 1 h
with horseradish peroxidase (HRP)-labeled goat anti-rab-
bit (CovalAb, Oullins, France) or goat anti-mouse (Santa
Cruz Biotechnology, Santa Cruz, CA) antibodies. Immu-
noreactive bands were visualised by a chemiluminescent
kit (Amersham, Zu¨rich, Switzerland) and quantified by
densitometry.
2.5. Preparation of cytosolic and particulate fractions
After stimulation, cells seeded in 90 mm Petri dishes
were washed with Tris/HCl buffer (20 mM, pH 7.5), 2
mM EDTA, 10 mM EGTA, 10 mM dithiothreitol, 0.25 M
sucrose and 30 AM leupeptin (buffer A), and homogenized
in 1 ml of the same buffer. The homogenate was centri-
fuged at 100,000 g for 1 h at 4 jC. The supernatant was
used as the cytosolic fraction. The pellet was incubated for
30 min at 20 jC with Triton X-100 (1% in buffer A),
diluted to the original volume of the homogenate with
buffer A (final Triton concentration 0.2%), and centrifuged
at 100,000 g for 1 h. The supernatant obtained was used
as the solubilized particulate fraction.
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Fig. 1. Effect of valeryl salicylate and NS-398 on AngII or PMA-induced
6-keto-PGF1a secretion in VSMC. Cells were stimulated for 1 h with 50
nM AngII or 100 nM PMA. Prior to stimulation, cells were left untreated
(5) or were preincubated for 2 h with 5 AM of valeryl salicylate (m) or
for 45 min with 1 AM NS-398 (n), respectively. 6-keto-PGF1a secretion
was determined as described in Section 2. Results represent the meansF
S.E.M. of three to four experiments performed in triplicate determinations.
*p< 0.05 vs. respective basal values.
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activity assay
PKC activity was almost undetectable in crude cell
fractions, but was expressed after DEAE-cellulose
chromatography.
Cytosolic and membrane fractions were applied to a
DEAE-cellulose column (2.5 0.9 cm), equilibrated at 4
jC in buffer B (20 mM Tris/HCl, pH 7.5, 2 mM EDTA, 2
mM EGTA and 10 mM dithiothreitol). The kinase activity
was eluted with a linear NaCl gradient (0–0.3 M) in
buffer B.
One hundred microliters of each fraction from the
column was assayed for PKC activity as previously de-
scribed [15]. Briefly, protein kinase activity was determined
by measuring the transfer of 32P from (g-32P)ATP to histone
III-S. The reaction mixture (240 Al) contained (0.7–
1.2) 106 c.p.m. of (g-32P)ATP, 0.15 AM ATP, 0.46 mM
CaCl2, 6.9 mM MgCl2 and 30 Ag of histone III-S. Each
fraction was assayed in the absence and presence of
phosphatidylserine (80 Ag) and diolein (4 Ag). After 10
min at 30j, the reaction was stopped with 2 ml of 12% (w/
v) trichloroacetic acid in the presence of g-globulin (600
Ag). After centrifugation (3000 g, 2 min), the pellet was
dissolved in 0.5 ml of 1 M NaOH and precipitated again
with 12% trichloroacetic acid. The precipitate was dis-
solved in 0.5 ml of 1 M NaOH, and 32P incorporation
was measured by scintillation counting.
2.7. PLD activity assay
VSMC were seeded into 90 mm Petri dishes. Confluent
cells were labelled for 15 h with [3H]-oleic acid (10 ACi; 10
Ci/mmol) and then washed to remove unincorporated label.
These labelled cells were incubated for 30 min at 37 jC with
5 ml of a Krebs–Ringer buffer [15], containing 0.2% fatty
acid free bovine serum albumin and 0.2% glucose at 37 jC,
in the presence and absence of PMA or AngII. Propanol
(0.5%) was added to the cells 5 min prior to the addition of
PMA or AngII. After incubation, the supernatant was
collected and the cells were washed before adding methanol
(4 ml/Petri). After harvesting the cells, lipids were extracted
according to Bligh and Dyer [16]. Radioactivity in aliquots
of medium, aqueous phase and chloroform phase was
determined. Lipid extracts were separated by thin layer
chromatography, with either the top phase of ethyl acetate/
2,2,4-trimethyl pentan/acetic acid/water (13:2:3:10) for sep-
aration of phosphatidylpropanol and phosphatidic acid or
with chloroform/methanol/acetic acid/water (100:50:16:3)
for separation of phospholipids.
2.8. Statistical analysis
Values were compared by analysis of variance (ANOVA)
using the Scheffe F-test criterion for unbalanced groups and
the Fisher’s protected least significant difference test when
M.A. Frias et al. / Cardiovasc440appropriate. Results represent the meansF S.E.M. of at least
three independent experiments.3. Results
3.1. AngII- and PMA stimulate COX-2 expression and PGI2
secretion in VSMC
Incubation of rat VSMC with AngII or PMA induced a
marked increase in cellular PGI2 secretion, as assessed by
the determination of its stable metabolite 6-keto-PGF1a
(Fig. 1, n = 3–4). Indeed, incubation of VSMC with 50 nM
AngII or 100 nM PMA for 1 h increased prostacyclin
production 8.8 and 4 times, respectively. In order to study
whether type 1 or type 2 cyclooxygenase (COX-1, COX-2)
are involved in this response we used their respective
inhibitors, valeryl salicylate [17] and NS-398 [18]. As
shown in Fig. 1, 2 h preincubation with 5 AM of valeryl
salicylate did neither significantly affect agonist-stimulated
nor basal PGI2 production. Similar results were obtained
with 50 AM of valeryl salicylate (data not shown). In
contrast, NS-398 (1 AM) abolished AngII- and PMA-
induced PGI2 secretion, but had no effect on basal pro-
duction. Our results indicate that in VSMC, AngII- and
PMA-induced PGI2 secretion is mediated by the activity of
COX-2, through a mechanism independent of COX-1.
We next investigated whether the synthesis of inducible
COX-2 was increased following 0.5–4 h incubation of cells
Fig. 3. Effect of AACOCF3 on AngII-induced COX-2 expression and PGI2
production in VSMC. (A) Western blot showing COX-2 expression: similar
results were obtained in three separate experiments. (B) Cells were
stimulated for 1 h with 50 nM AngII, and 6-keto-PGF1a secretion was
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induced a rapid significant increase in COX-2 amount,
which remained sustained during 4 h of agonist stimulation.
Thus, our results demonstrate that in the signaling pathway
leading to prostacyclin formation in VSMC, AngII and
PMA increase both the expression and the activity of
cyclooxygenase-2.
In parallel, we also investigated the role of cytosolic
phospholipase A2 (cPLA2) by using the specific cPLA2
inhibitor arachidonyl trifluoromethyl ketone (AACOCF3)
[19]. As shown in Fig. 3, preincubation with 30 AM
AACOCF3 for 30 min had no effect on basal PGI2
production, but abolished the AngII-induced response. By
contrast, AACOCF3 did not affect COX-2 expression,
neither in control nor in AngII-stimulated cells, indicating
that in VSMC, cPLA2 activation is a necessary step for
AngII-induced PGI2 secretion, independent of COX-2
synthesis.
In order to determine whether protein synthesis is in-
volved in AngII- and PMA-induced COX-2 expression as
well as prostacyclin secretion, we tested the effect of
cycloheximide on these two parameters in VSMC. Fig. 4
determined. Prior to stimulation, cells were left untreated (5) or were
preincubated for 30 min with 30 AM of AACOCF3 (m). Results represent
the meansF S.E.M. of three experiments performed in triplicate determi-
nations. *p< 0.05 vs. basal control values.
Fig. 4. Effect of cycloheximide on agonist-induced COX-2 expression and
6-keto-PGF1a formation in VSMC. Cells were stimulated for 1 h with 50
nM AngII or 100 nM PMA. Prior to stimulation, cells were left untreated
(C, 5) or were preincubated for 15 min with 10 Ag/ml of cycloheximide
(CHX, m). (A) Western blot showing COX-2 expression: similar results
were obtained in three separate experiments. (B) Production of 6-keto-
PGF1a: results represent the meansF S.E.M. of three to four experiments
performed in triplicate determinations. *p< 0.05 vs. basal control values.
Fig. 2. Agonist-induced increase in COX-2 expression in VSMC. Cells
were incubated with 50 nM AngII or 100 nM PMA for the indicated periods
of time. (A) Cells were lysed and Western blotting was performed using an
anti-COX-2 antibody. Equal protein loading was confirmed by non-specific
bands (NS). (B) Specific bands corresponding to COX-2 amount were
quantified by densitometry and expressed as percentage of control. Results
represent meansF S.E.M. of values obtained in three to four experiments.
*p< 0.05 vs. control values.
Fig. 5. Effect of AngII and PMA stimulation on subcellular location of PKC
activity in VSMC. Cells were stimulated with 50 nM AngII or 100 nM
PMA for 30 min or they were, prior to stimulation, pretreated for 48 h with
100 nM PMA. Membrane and cytosolic cell fractions were assayed for
PKC activity as described in Section 2. The figure shows data pooled from
four independent experiments. Mean valuesF S.E.M. are expressed as
percentages of control values. *p< 0.05 vs. respective basal values.
Fig. 6. Effect of PKC downregulation and PKC inhibition on COX-2
expression in VSMC. Western blot showing COX-2 expression: similar
results were obtained in three separate experiments. (A) Cells were
incubated for 1–48 h with 100 nM PMA. (B) VSMC were stimulated for
1 h with 50 nM AngII or 100 nM PMA. Prior to stimulation, cells were
left untreated (C) or, to downregulate PKC, they were preincubated for 48
h with 100 nM PMA (Down). (C) Cells were incubated for 1 h with 50
nM AngII or 100 nM PMA in the presence or absence of 1 AM
CGP41251 (CGP).
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induced by AngII or PMA were abolished in cells preincu-
bated for 15 min with 10 Ag/ml cycloheximide. These data
indicate that in VSMC, newly synthesized proteins are
necessary not only for AngII- and PMA-induced COX-2
expression but also for the PGI2 secretion stimulated by
these agonists.
3.2. Effects of AngII and PMA stimulation on PKC activity
in VSMC
We studied the changes in PKC activity occuring in
cytosolic and membranous fractions of VSMC incubated
with AngII or PMA. As is shown in Fig. 5, exposure of
these cells to 50 nM AngII or 100 nM PMA for 30 min
increased basal membranous PKC activity by 120F 13%
and by 209F 29%, respectively. By contrast, basal cytosolic
PKC activity was decreased by 55F 5% in PMA-treated
cells, while it was not significantly changed in AngII-
incubated cells.
Following 48 h of exposure to PMA, PKC activity was
abolished in both the membranes and the cytosol and could
no longer be stimulated neither by AngII nor by PMA,
indicating a complete PKC downregulation.3.3. Role of PKC in AngII- and PMA-induced COX-2
expression and PGI2 secretion in VSMC
To answer the question whether PKC activation is
necessary for AngII and PMA-induced COX-2 expression
and PGI2 production, we used the PKC inhibitor CGP41251
[20] as well as PKC-depleted cells (48 h exposure to 100
nM PMA). Fig. 6A shows that the rapid increase in COX-2
expression, induced by PMA, decreased following pro-
longed incubation with PMA, finally reaching control levels
after 48 h.
Densitometric analysis of three Western blots, similar to
that shown in Fig. 6B, revealed that in PKC-depleted cells
(48 h PMA) AngII- and PMA-induced COX-2 expression
was reduced by 75F 6% and 94F 6%, respectively, when
compared to non-treated cells. Likewise, as shown in Fig.
6C, the presence of the PKC inhibitor CGP41251 (1 AM)
abolished PMA-induced COX-2 expression and inhibited
AngII-promoted COX-2 increase by 72F 9% (n = 3).
Concerning prostacyclin production, we observed that
after 48 h of incubation with PMA, resulting in a complete
PKC downregulation, AngII- and PMA-induced PGI2 re-
lease was inhibited by 82F 5% and 95F 3%, respectively,
when compared to non-pretreated cells (Fig. 7, panel A).
Similar to the effect of PKC downregulation, the presence of
the PKC inhibitor CGP41251 (1 AM) reduced AngII- and
PMA-stimulated PGI2 release by 86F 3% and 98F 1%,
respectively (n = 3, Fig. 7, panel A).
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Fig. 8. Effect of AngII and PMA on PLD activity in VSMC. Cells were
labeled with [3H]-oleic acid as described in section 2, washed and
stimulated for the indicated periods of time with 50 nM AngII or 100 nM
PMA. PLD activity was determined by measuring the production of [3H]-
phosphatidic acid ([3H]-PA) in the absence of alcohol (panel A), and by
measuring the formation of [3H]-phosphatidylpropanol ([3H]-PtProp) in the
presence of 0.5% propanol (panel B). The figure shows mean
valuesF S.E.M. pooled from three to five independent experiments.
*p< 0.05 vs. control values.
Fig. 7. Role of PKC on AngII- and PMA-induced prostacyclin production
and PLD activity in VSMC. Cells were incubated for 1 h with 50 nM AngII
or 100 nM PMA in the presence or absence of 1 AM CGP41251 or prior to
stimulation, they were pretreated with 100 nM PMA for 48 h. Panel A:
Determination of 6-keto-PGF1a release. Panel B: PLD activity was
determined by measuring [3H]-phosphatidylpropanol ([3H]-PtProp) for-
mation in the presence of 0.5% propanol as described in section 2. The
figure shows mean valuesF S.E.M. from three to five independent
experiments. *p< 0.05 vs. respective basal values.
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AngII- and PMA-induced COX-2 expression and PGI2
secretion in aortic smooth muscle cells.
3.4. AngII and PMA induce PLD activity in VSMC
We evaluated the formation of phosphatidic acid (PA)
following stimulation with AngII and PMA. VSMC were
labelled with [3H]-oleic acid for 15 h. As shown in Fig.
8 (panel A), both AngII (50 nM) and PMA (100 nM)
induced a marked increase in [3H]-phosphatidic acid for-
mation in these cells.
Indeed, AngII rapidly increased the production of [3H]-
phosphatidic acid reaching a peak within 15 min, whereas
PMA-induced [3H]-phosphatidic acid formation reached
similar values only after 30 min of stimulation.
Since phosphatidic acid may be generated not only by the
PLD-mediated hydrolysis of glycerophospholipids but also
by the phosphorylation of diacylglycerol, we further
assessed the contribution of PLD in agonist-induced [3H]-
phosphatidic acid production measuring transphosphatidy-
lation of primary alcohol which is a more specific marker
for PLD activity [21]. In the presence of 0.5% propanol,
AngII (50 nM) and PMA (100 nM) generated the produc-
tion of [3H]-phosphatidylpropanol (Fig. 8, panel B), paral-
leled by an approximately 70% decrease in [3H]-
phosphatidic acid formation (data not shown). Indeed,AngII rapidly stimulated [3H]-phosphatidylpropanol pro-
duction reaching a plateau at 15 min (Fig. 8, panel B).
Initially, PMA induced lower levels of [3H]-phosphatidyl-
propanol compared to AngII; however, similar values were
obtained after 30 min of stimulation (Fig. 8, panel B).
Exposure of cells to AngII or PMA in the absence of
propanol did not result in the formation of [3H]-phosphati-
dylpropanol (data not shown).
3.5. Role of PKC in AngII- and PMA-induced PLD activity
in aortic smooth muscle cells
PLD activity was assessed by measuring the trans-
phosphatidylation of primary alcohol. As shown in Fig.
7, panel B, exposure of VSMC to 50 nM AngII or 100
nM PMA for 1 h in the presence of 0.5% propanol
increased [3H]-phosphatidylpropanol production from
452F 31 to 4871F 593 and 5516F 689 cpm/mg cell
protein, respectively.
Fig. 9. Effect of 1-butanol and dioctanoyl PA on COX-2 expression and
6-keto-PGF1a secretion in VSMC. Each Western blot shown is
representative of three independent experiments. (A) Cells were incubated
for 1 h with 50 nM AngII in the presence or in the absence of 1% 1-butanol
(BuOH). (B) Cells were exposed to 0.2 mM dioctanoyl PA (PA) for the
indicated periods of time. (C) Cells were incubated for 1 h with the
indicated concentrations of dioctanoyl PA (PA). (D) Production of 6-keto-
PGF1a in cells stimulated for 1 h with 50 nM AngII in the presence or in the
absence of 1% 1-butanol (BuOH) and in cells incubated for 1 or 2 h with
0.1 and 0.2 mM dioctanoyl PA (PA).
Fig. 10. Major pathways involved in AngII-induced PGI2 production in
VSMC. Angiotensin ll (AngII) activates protein kinase C (PKC) leading to
increased phospholipase D (PLD) activity and subsequent augmentation of
phosphatidic acid (PA) which in turn induces cyclooxygenase (COX-2)
expression and prostacyclin (PGI2) secretion. On the other hand, AngII-
induced cytosolic phospholipase A2 (cPLA2) activation, providing
arachidonic acid (AA), is a necessary step for PGI2 production.
Abbreviations: CGP41251, PKC inhibitor; 48 h PMA, incubation of
VSMC with PMA for 48 h leading to PKC downregulation; AACOCF3,
cPLA2 inhibitor; BuOH (1-butanol) inhibitor of PLD activity; NS-398,
COX-2 inhibitor.
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incubation with PMA, resulting in PKC downregulation,
AngII and PMA no longer increased PLD activity (Fig. 7,
panel B). Likewise, the presence of the PKC inhibitor
CGP41251 (1 AM) abolished both the AngII- and the
PMA-stimulated PLD activity.
These data indicate that PKC plays an important role in
AngII- and PMA-induced PLD activation in VSMC.
3.6. Role of PLD in AngII-induced COX-2 expression and
PGI2 secretion in VSMC
To assess whether PLD activity is involved in AngII-
induced COX-2 expression and PGI2 release, we used 1-
butanol (BuOH) which is known to suppress PLD action
mainly by inhibiting phosphatidic acid (PA) formation.
VSMC were incubated for 1 h with 50 nM AngII in the
absence or in the presence of 1% BuOH. As illustrated inFig. 9A and D, BuOH abolished both, AngII-induced COX-
2 expression and PGI2 release, without affecting basal
values. To provide further evidence that PA is involved in
COX-2 expression as well as in PGI2 production, cells were
incubated for 1–6 h with 0.1–0.5 mM of a short-chained
dioctanoyl PA. Fig. 9B–D shows that dioctanoyl PA in-
duced COX-2 expression as well as PGI2 release in a time-
and concentration-dependent manner. These data indicate
that PLD activation and PA formation are involved in
AngII-induced COX-2 expression and PGI2 secretion in
VSMC.4. Discussion
This study demonstrates that in VSMC, AngII promotes
PGI2 secretion to a large extent by a PKC-dependent
induction of COX-2 via an increase in PLD activity and
subsequent augmentation of PA. The signaling pathway
follows the sequence AngII–PKC–PLD–PA–COX-2–
PGI2 (Fig. 10).
Moreover, the present work shows that in VSMC,
AngII-induced PGI2 secretion is mediated by the activities
of both cPLA2 and COX-2, through a mechanism inde-
pendent of COX-1. The fact that the cPLA2-specific
inhibitor AACOCF3 did neither effect basal nor agonist-
induced COX-2 expression suggests that cPLA2 activity is
not involved in COX-2 synthesis, but is rather necessary
for COX-2 activity by providing arachidonic acid.
AngII and PMA promoted the translocation of PKC
activity from the cytosol to the membranes within 30 min,
followed by a marked increase in PLD activity as well as
COX-2 expression and PGI2 production. After 48 h of
exposure to PMA, membrane and cytosolic PKC activities
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stimulated by AngII or PMA. In these PKC-depleted cells,
as well as in the presence of the PKC inhibitor CGP41251
[20], both the PMA- and the AngII-induced activation of
PLD was abolished. Under the same conditions, the
stimulatory effect of PMA on COX-2 expression and
PGI2 production was also completely suppressed, whereas
that of AngII was strongly inhibited. This difference can
be explained by the fact that PMA directly activates PKC
while AngII acts through phosphatidylinositol 4,5-bisphos-
phate hydrolysis, thus increasing not only membranous
PKC activity but also intracellular free calcium concentra-
tion ([Ca2 +]i) which contributes to the regulation of PGI2
secretion in hormone-stimulated VSMC [15]. Moreover,
our data provide indirect evidence that increased [Ca2 +]i is
not involved in AngII-stimulated PLD activity in VSMC
which is in agreement with recent work reporting that in
adrenal glomerulosa cells, AngII-induced PLD activation is
independent of calcium influx [8].
Our data present strong evidence that in aortic smooth
muscle cells, AngII-induced PLD activation and subsequent
increase in COX-2 expression and PGI2 release occurs to a
great extent via the activation of PKC. Two earlier studies
[22,23] reported that following 24 h exposure of VSMC to
PMA, the AngII-induced PLD activation was not affected,
suggesting that PKC is not involved in this process. We
obtained similar results after 24 h incubation of VSMC with
PMA, but we also observed that in these cells, PKC activity
was not completely suppressed and could still be tripled
upon addition of AngII (unpublished results). Our results,
obtained with PKC-depleted VSMC after 48 h of exposure
to PMA and with cells incubated with the PKC inhibitor
CGP41251, are in agreement with previous reports indicat-
ing that PKC is an important regulator of PLD activity (for
review, see Ref. [7]). However, Andresen et al. [9] reported
that in preglomerular microvascular smooth muscle cells,
AngII-stimulated PLD activity was not affected by pharma-
cological inhibition of PKC. These different observations
suggest a tissue-specific role for PKC in the regulation of
PLD activity. Moreover, depending on the cell type, PLD
activity can also be modulated positively or negatively by
protein kinase A [24,25].
To assess the link between PLD activation on one hand,
and COX-2 expression and PGI2 production on the other
hand, we stimulated VSMC with AngII in the presence of
1-butanol which leads to the formation of phosphatidyle-
thanol instead of PA. We found that in these cells, 1-
butanol abolished AngII-induced COX-2 expression and
PGI2 secretion. Moreover, the short-chain dioctanoyl PA
increased COX-2 expression and PGI2 production in a
time- and concentration-dependent manner. These observa-
tions suggest that AngII-induced COX-2 expression and
subsequent increase in PGI2 production is to a great extent
mediated by PA resulting from PLD activation. In agree-
ment with our results, PLD was reported to be involved in
the regulation of COX-2 expression in amnion-derivedWISH cells stimulated by interleukin-1h [13] and phorbol
ester [12].
Our investigations concerning the role of PKC and PLD
in AngII-stimulated PGI2 release indicate that induction of
COX-2 plays a key role in this response. Concomitant with
increased or decreased PGI2 production in VSMC, we
observed corresponding changes in COX-2 expression lev-
els. The importance of increased COX-2 expression in
AngII- and PMA-stimulated PGI2 release was further con-
firmed by the observations that AngII- and PMA-induced
PGI2 production depended on newly synthesized proteins
and COX-2 activity, while COX-1 was not involved.
Overall, our study resulted in new, complementary
information concerning the mechanism involved in AngII-
stimulated PGI2 secretion in VSMC. The investigation of
Ohnaka et al. [2] provided evidence that AngII regulates
COX-2 expression and prostaglandin production through
MAP kinase-mediated signaling pathways in VSMC. In
A10 cells, a vascular smooth muscle cell line, the stimula-
tion of MAPK phosphorylation by AngII is inhibited in the
absence of PLD activity, and addition of phosphatidic acid
restores the effect of AngII on MAPK phosphorylation
[26]. Our investigation provide evidence that in VSMC,
AngII-stimulated PGI2 production occurs to a great extent
through a rise in COX-2 expression which is mediated by
PA generated from increased PKC-dependent PLD activity.Acknowledgements
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